

A Critical Appraisal of the Intrinsic Pancreatic Angiotensin-Generating System

Conrad Sernia

Department of Physiology and Pharmacology, University of Queensland, Queensland, Australia

Summary

The pancreas is a relative newcomer to the stable of tissues with an intrinsic angiotensin-generating system. The involvement of this system in pancreatic activity will be dependent on the angiotensin-generating paths present in the pancreas and their precise cellular location. Thus far, renin, angiotensin-converting enzyme (ACE), angiotensin II and AT₁ and AT₂ receptors have been found. These are components of the "classical" renin-angiotensin system. But there is uncertainty as to their location and site of action. Furthermore, it is not known which, if any, alternative enzymes to renin and ACE are present, which angiotensins in addition to angiotensin II are generated and whether or not there are receptors to angiotensin IV and angiotensin-(1-7). Future research should focus on these aspects in order to provide a mechanistic basis to pancreatic physiological functions and to pathological conditions of clinical relevance.

Introduction

The enzymatic pathway, which leads to the generation of the potent vasoconstrictor octapeptide angiotensin II, is usually understood in terms of the "renin-angiotensin system" (RAS) [1, 2, 3], where the hepatic glycoprotein angiotensinogen is hydrolyzed by the renal enzyme renin in the circulating blood. The decapeptide product, angiotensin I is subsequently converted to angiotensin II by the pulmonary membrane-bound angiotensin converting-enzyme (ACE). This classical

model has been incorporated in the illustration in Figure 1. However this pathway to angiotensin II generation is truly skeletal. In the context of contemporary research it is more constructive to view the RAS as consisting of obligatory components (angiotensinogen, angiotensin II and specific receptors) linked by alternative, non-exclusive components (renin, ACE and their functional homologues [4, 5]). It is therefore more accurate to describe the RAS as a major "angiotensin-generating system", rather than the definitive enzymatic cascade of angiotensin II generation. The classical description of the RAS also undermines the reality that angiotensin II formation is not restricted to the circulation but is formed in numerous tissues as diverse in function as the brain [1, 6, 7], pituitary [6, 8], heart [9], kidney [10], gonads [11, 12], and pancreas (*vide infra*). It may even be formed intracellularly [8, 10, 13]. The emphasis on angiotensin II as the biologically relevant product has also undergone extensive revision, as what were once regarded metabolic "fragments" of angiotensin II have become products with specific actions mediated by selective receptors [14]. For example angiotensin III is involved in the central regulation of blood pressure and preferentially binds to the AT_{1b} receptor [15, 16], angiotensin IV has vasodilatory, antiproliferative and cognitive actions [17, 18] and angiotensin-(1-7) is a vasorelaxant [19, 20, 21]. The final level of complexity is added by the variety of angiotensin (AT) receptors. Presently the major recognized AT receptors includes the AT₁ (subtypes a and b)

and AT₂ receptors for angiotensin II and angiotensin III action [1, 2, 3, 9]. Although the gene has yet to be identified, there is strong evidence that angiotensin IV acts via an AT₄ receptor [22], and on the basis of the heterogeneity of ligand binding, via a second AT_{4b} receptor subtype [23]. There is evidence for an AT-(1-7) binding site for angiotensin-(1-7) action, but a definitive identification of this binding site has thus far eluded researchers [19, 20, 21]. This array of enzymatic paths leading to several biologically active angiotensins, targeting tissues with their respective receptors, is a distant and vastly different system from the classical RAS. Its complexity provides the opportunity for functional diversity and for multiple levels of control points. The elucidation and understanding of these angiotensin-generating systems has led to a corresponding expansion of the domain for angiotensin action, far beyond its modest beginning as a vasoconstrictor hormone.

Renin-Angiotensin System




Figure 1. Diagram of the classical renin-angiotensin II pathway with additional biologically active angiotensins and their receptors.

Angiotensin-Generating Systems in the Pancreas

Evidence for intrinsic angiotensin-generating systems has been found in pancreatic tissues and cell lines of the mouse, rat, dog and man [24, 25, 26, 27, 28, 29]. The evidence has been summarized in Table 1. The protein for the obligatory component angiotensinogen has been reported for the rat [24] and dog [25] pancreas and its mRNA identified by reverse transcriptase polymerase chain reaction (RT-PCR). Immunocytochemistry has shown it to be localized in the epithelium of pancreatic ducts and in the vascular endothelium [24]. The islet cells do not show angiotensinogen immunocytochemically, yet islet cell lines do express angiotensinogen [30]. Thus a low or intermittent expression of angiotensinogen in islet cells in particular stimulatory circumstances, such as hypoxia [31], pancreatitis [32, 33] or other inflammatory conditions, should not be overlooked. The tissue content of angiotensinogen is low compared to blood [25], indicating the presence of highly localized angiotensin generation in the vasculature and ducts, and possibly the islets. Renin, (more precisely, prorenin), has been identified in the human pancreas [26]. While renin was localized by immunocytochemistry to the vascular endothelium and beta-cells, renin mRNA was found in vascular fibroblasts and reticular fibres of the islets. This cellular separation of prorenin from its mRNA suggests that prorenin may be used in the intracellular generation of angiotensin II by endothelium and beta-cells, in addition to any extracellular role. There is partial support for an intracellular angiotensin II system from the findings of Leung *et al* [29], which localized angiotensin II immunocytochemically to endothelial cells and ductal epithelia. However they found no angiotensin II in islet cells, implying that the renin in beta-cells [24] is not used to generate angiotensin II or more likely, that angiotensin II is formed and immediately secreted. This secreted angiotensin II would then act in a paracrine fashion on beta-cells via AT₁ receptors and on adjacent islet cells which, at least in the

rodent, express higher densities of AT receptors than beta-cells [34]. The direct function of angiotensin II on islets cells may well be the regulation of cell growth rather than the regulation of hormone secretion [35, 36]. ACE is predictably found in the vascular endothelium, preferentially in the islet vasculature [37], as well as in islet cells [36]. One of the striking features of the research on the angiotensin-generating systems in the pancreas is the coincidence in the localization of renin, angiotensinogen and angiotensin II.

Based on these current observations the predominant pathway to angiotensin II production in the pancreas strongly favours the classical angiotensinogen-renin-ACE axis. The failure to detect angiotensin I by Chappell *et al* [25] seems to undermine this view, until one considers that these authors also failed to detect renin activity as well, in contrast to later studies using renin-specific techniques [24, 26].

Table 1. Summary of the presence or absence and the location in the pancreas of major components of the renin-angiotensin system.

RAS component	Absence/Presence	Location	Reference
Angiotensinogen	Present	Epithelium of ducts, Vascular endothelium	[24, 25]
(Pro)renin	Present	Beta-cells (protein) Fibroblasts (mRNA)	[24, 26]
Angiotensin-converting enzyme (ACE)	Present	Vasculature, Pancreatic cell line	[36, 37]
Angiotensin II	Present	Ductal epithelium, Vascular endothelium	[29]
Angiotensin III	Present	?	[25]
Angiotensin IV	?	?	
Angiotensin-(1-7)	Present	?	[25]
AT ₁ receptor	AT _{1a} , AT _{1b} present	Throughout pancreas	[24, 26, 27, 28, 31, 34]
AT ₂ receptor	Present	Throughout pancreas	[24, 27, 28, 34]
AT ₄ receptor	?	?	
AT-(1-7) site	?	?	

Receptors, which mediate angiotensin II action, have a widespread distribution in the pancreas [26, 27, 28, 31, 33, 34, 38, 39]. The abundance of AT₂ receptors appears to be greater than AT₁ receptors [27, 34], nevertheless their distribution covers islets cells, acinar cells, duct cells and vascular tissue. Such a wide distribution is an indication of the variety of roles in which angiotensin II is likely involved in addition to the already established regulation of pancreatic blood [37] and ducal anion secretion [40]. Further support for this view is provided by the presence of both AT_{1a} and AT_{1b} subtypes and the predominance of AT₂ receptors [24, 26, 27, 28, 34], which are known to mediate growth and differentiation in direct opposition to AT₁-mediated actions [9, 41]. It is thus appropriate that the pancreatic RAS be considered of importance

in conditions like pancreatitis, hypoxia and in any inflammatory pancreatic event. While there is an impressive amount still to be uncovered about the “classical” pancreatic RAS, the most deficient area is in the investigation of alternate pathways to the production of angiotensins [1, 2, 4, 5, 14, 15], and in the expression of non-angiotensin II AT receptors [3, 18, 20, 22]. Kallikreins capable of generating angiotensin II independently of renin are present in the pancreas [5], thus implying the potential for alternative angiotensin II generating pathways. In addition, angiotensin III and angiotensin-(1-7) have been identified, albeit at lower concentrations than angiotensin II, in the canine pancreas [25]. Their presence implies the existence of aminopeptidases capable of cleaving these peptides directly from angiotensinogen or from angiotensin II.

However, the peptidases or proteases responsible for angiotensin II and angiotensin-(1-7) production have not been identified in the pancreas. It is interesting that insulin has the ability to change the activity of aminopeptidases capable of angiotensin hydrolysis [42]. Hence there may be a reciprocal role between insulin regulation of local angiotensins production and the RAS regulation of pancreatic activity. Angiotensin-(1-7), having actions which oppose those of angiotensin II [19, 20, 21], raises the possibility of differential blood flow in the pancreas due to a balance between angiotensin II and angiotensin-(1-7). The present limited data do not allow more than speculation on this possibility. Finally, the hexapeptide angiotensin IV has in recent times attracted a great deal of attention because of its vasodilatory, antihypertrophic and cognitive-enhancing actions [3, 17, 18]. Furthermore, there is at least one AT₄ receptor site selective for angiotensin IV that has been partially characterized [22]. Based on ligand-binding heterogeneity, there may be a second AT_{4b} site [23]. There is no information on any aspect of angiotensin IV physiology in the pancreas. The peptide has not been identified or localized nor has its function been tested. Similarly, AT₄ receptors have not been identified and localized in the pancreas.

Future Directions

The current evidence for an intrinsic RAS in the pancreas is persuasive and indicates that it is of importance in normal exocrine and endocrine functions, as well as in pathological conditions. There is still uncertainty as to the precise location of the components, their relative abundance and which intracellular or extracellular pathways are operative in the generation of angiotensin II. However, the least understood aspects are found in our understanding of the "non-classical" RAS which contains enzymes alternative to ACE and renin, the production of biologically active angiotensins in addition to angiotensin II and the presence of receptors for these additional angiotensin peptides. These areas

of research should lead to a fuller understanding of the mechanisms which operate in the normal pancreas and how their derangement leads to pathological manifestations, and *vice versa*.

Key words Angiotensins; Receptors, Angiotensin; Renin-Angiotensin System; Pancreas; Tissues

Correspondence

Conrad Sernia

Department of Physiology and Pharmacology
University of Queensland
Queensland, 4072

Australia

Phone: +617-3365-3180

Fax: +617-3365-1766

E-mail address: c.sernia@mailbox.uq.edu.au

References

1. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. *Regul Pept* 1993; 43:1-20. [93150166]
2. Stroth U, Unger T. The renin-angiotensin system and its receptors. *J Cardiovasc Pharmacol* 1999; 33 (Suppl. 1):S21-8. [99151408]
3. Zhuo J, Moeller I, Jenkins T, Chai SY, Allen AM, Ohishi M, Mendelsohn FAO. Mapping tissue angiotensin-converting enzyme and angiotensin AT₁, AT₂ and AT₄ receptors. *J Hypertens* 1998; 16:2027-37.
4. Arakawa K. Serine protease angiotensin II systems. *J Hypertension* 1996; 14 (Suppl.):S3-7.
5. Hojima Y, Yamashita N, Ochi N, Moriwaki C, Moriya H. Isolation and properties of dog and rat pancreatic kallikreins. *J Biochem* 1977; 81:599-610.
6. Sernia C, Zeng T, Kerr D, Wyse B. Novel perspectives on pituitary and brain angiotensinogen. *Front Neuroendocrinol* 1997; 18:174-208. [97255928]
7. Thomas WG, Sernia, C. Immunocytochemical localization of angiotensinogen in the rat brain. *Neuroscience* 1988; 25:319-41.
8. Thomas WG, Sernia C. Angiotensinogen and angiotensin in the rat pituitary: an immunocytochemical study. *J Neuroendocrinol* 1990; 2:110-8.

9. Dostal DE. The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function. *Regul Pept* 2000; 91:1-11. [20425227]
10. Celio MR. Angiotensin II immunoreactivity coexists with renin in the juxtaglomerular granular cells of the kidney. *Proc Natl Acad Sci USA* 1981; 78:3897-900.
11. Vinson GP, Saridogan E, Puddefoot JR, Djahanbakhch O. Tissue renin-angiotensin systems and reproduction. *Hum Reprod* 1997; 12:651-62. [97302988]
12. Thomas WG, Sernia C. The immunocytochemical localization of angiotensinogen in the rat ovary. *Cell Tiss Res* 1990; 261:367-73.
13. Sadoshima J, Xu Y, Slater HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. *Cell* 1993; 75:977-84.
14. Moeller I, Allen AM, Chai SY, Zhuo J, Mendelsohn FA. Bioactive angiotensin peptides. *J Hum Hypertens* 1998;12:289-93.
15. Reaux A, Iturriz X, Vazeux G, Fournie-Zaluski M, David C, Roques BP, et al. Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. *Biochem Soc Trans* 2000; 28:435-40.
16. Rowe BP, Dixon B. Angiotensin III depressor action in the conscious rabbit is blocked by losartan but not PD 123319. *Hypertension* 2000; 35:130-4.
17. Kramar EA, Krishnan R, Harding JW, Wright JW. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. *Regul Pept* 1998; 74:185-92. [98375998]
18. Wright JW, Krebs LT, Stobb JW, Harding JW. The angiotensin IV system: functional implications. *Front Neuroendocrinol* 1995; 16:23-52. [95285930]
19. Ferrario CM, Iyer SN. Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. *Regul Pept* 1998; 78:13-8. [99094351]
20. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. *Regul Pept.* 2000; 91:45-62. [20425231]
21. Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, van Gilst WH. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. *Hypertension* 1999; 34:296-301.
22. Briand SI, Bellemare JM, Bernier SG, Guillemette G. Study on the functionality and molecular properties of the AT₄ receptor. *Endocr Res* 1998; 24:315-23.
23. Greenland KJ, Wyse B, Sernia C. Identification and characterisation angiotensin IV binding sites in rat neuronal and astrocyte cell cultures. *J Neuroendocrinol* 1996; 8:687-93.
24. Leung PS, Chan WP, Wong TP, Sernia C. Expression and localization of the renin-angiotensin system in the rat pancreas. *J Endocrinol* 1999; 160:13-9. [99077887]
25. Chappell MC, Millsted A, Diz DI, Brosnihan KB, Ferrario CM. Evidence for an intrinsic angiotensin system in the canine pancreas. *J Hypertens* 1991; 9:751-9. [92012988]
26. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. *J Endocrinol* 1999; 161:317-22. [AN; 99271012]
27. Chappell MC, Diz DI, Jacobsen DW. Pharmacological characterization of angiotensin II binding sites in the canine pancreas. *Peptides* 1992; 13:313-8. [93027675]
28. Leung PS, Chan HC, Fu LXM, Wong PYD. Localization of angiotensin II receptor subtypes AT₁ and AT₂ in the pancreas of rodents. *J Endocrinol* 1997; 153:269-74. [97308925]
29. Leung PS, Chan HC, Wong PY. Immunohistochemical localization of angiotensin II in the mouse pancreas. *Histochem J* 1998; 30:21-5. [98198607]
30. Brasier AE, Philippe J, Campbell DJ, Habener JF. Novel expression of the angiotensinogen gene in a rat pancreatic islet cell line. *J Biol Chem* 1986; 261:16148-54. [87057283]
31. Chan WP, Fung LM, Nobiling R, Leung PS. Activation of local renin-angiotensin system by chronic hypoxia in rat pancreas. *Mol Cell Endocrinol* 2000; 160:107-14. [20181765]
32. Greenstein RJ, Krakoff LR, Felton K. Activation of the renin system in acute pancreatitis. *Am J Med* 1987; 82:401-4. [87153404]
33. Leung PS, Chan WP, Nobiling R. Regulated expression of pancreatic renin-angiotensin system in experimental pancreatitis. *Mol Cell Endocrinol* 2000; 166:121-8. [20453048]
34. Ghiani BU, Masini MA. Angiotensin II binding sites in the rat pancreas and their modulation after sodium loading and depletion. *Comp Biochem Physiol A Physiol* 1995; 111:439-44. [95338780]
35. Dunning BE, Moltz JH, Fawcett CP. Actions of neurohypophysial peptides on pancreatic hormone release. *Am J Physiol* 1984; 246:E108-14.
36. Redpy MK, Baskaran K, Moiteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. *Soc Exp Biol Med* 1995; 210:221-6.
37. Carlsson PO. The renin-angiotensin system in the exocrine pancreas. *JOP. J. Pancreas (Online)* 2001; 2:26-32.

38. Cheung WT, Yeung SY, Yiu AK, Ip TM, Wan DC, Luk SK, Ho WK. Characterization of a functional AT_{1a} angiotensin receptor in pancreatoma AR4-2J cells. *Peptides* 1999; 20:829-36.
39. Chappell MC, Jacobsen DW, Tallant EA. Characterization of angiotensin II receptor subtypes in pancreatic acinar AR42J cells. *Peptides* 1995; 16:741-7. [96065520]
40. Chan HC, Law SH, Leung PS, Fu LX, Wong PYD. Angiotensin II receptor type I-regulated anion secretion in cystic fibrosis pancreatic duct cells. *J Membr Biol* 1997; 156:241-50. [97252709]
41. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, et al. The angiotensin II type 2 (AT₂) receptor antagonizes the growth effects of the AT₁ receptor: gain-of-function study using gene transfer. *Proc Natl Acad Sci USA* 1995; 92:10663-7. [96068676]
42. Herbst JJ, Ross SA, Scott HM, Bobin SA, Morris NJ, Lienhard GE, Keller SR. Insulin stimulates cell surface aminopeptidase activity toward vasopressin in adipocytes. *Am J Physiol* 1997; 272:E600-6.